A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors

Bibliographic Details
Main Authors:	Pacey, S, Blackhall, F, Garcia-Corbacho, J, Lipplaa, A, Fusi, A, Kumar, S, Hategan, M, Derham, J, Laviste, G, Halford, S, Foxton, C, McLeod, R, Wan, S, Talbot, D
Format:	Conference item
Published:	Oxford University Press 2016

Similar Items

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
by: Kirkwood, J, et al.
Published: (2012)

Selumetinib - a potential small molecule inhibitor for osteoarthritis treatment
by: Xiaohang Zheng, et al.
Published: (2022-09-01)

Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review
by: Michele Basilicata, et al.
Published: (2024-01-01)

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
by: Brave, SR, et al.
Published: (2011)

Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration
by: Meredith, Erik L., et al.
Published: (2016)

In vitro effects of vandetanib on VEGFR2, EGFR and RET phosphorylation, endothelial cell tube formation, and tumor cell growth and survival
by: Brave, SR, et al.
Published: (2007)

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
by: Gupta, A, et al.
Published: (2014)

Identification of the Major Degradation Pathways of Selumetinib
by: Tahar Sif eddine Bouchema, et al.
Published: (2022-11-01)

Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma
by: Qian Zhao, et al.
Published: (2022-11-01)

Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib
by: Kateřina Jáklová, et al.
Published: (2021-04-01)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
by: Leijen, S, et al.
Published: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
by: Leijen, S, et al.
Published: (2011)

MEK inhibitors for the treatment of extracranial arteriovenous malformations
by: Zi’an Xu, et al.
Published: (2023-09-01)

MEK inhibitors for the treatment of NRAS mutant melanoma
by: Sarkisian S, et al.
Published: (2018-08-01)

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
by: Leijen, S, et al.
Published: (2012)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
by: Mattia Garutti, et al.
Published: (2022-12-01)

Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib
by: Sami Znati, et al.
Published: (2020-07-01)

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
by: Gupta, A, et al.
Published: (2013)

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations
by: Xuan Wang, et al.
Published: (2023-01-01)

P1097: MEK-INHIBITORS IN TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS
by: E. Burtsev, et al.
Published: (2022-06-01)

Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma
by: Svenja Mergener, et al.
Published: (2021-06-01)

PEDIATRIC LOW-GRADE GLIOMAS AND MEK INHIBITORS – CASE REPORT
by: Urša Jenko, et al.
Published: (2023-10-01)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
by: Elizabeth Turner, et al.
Published: (2022-11-01)

Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
by: Lei Wang, et al.
Published: (2024-01-01)

Photoswitchable Azo- and Diazocine-Functionalized Derivatives of the VEGFR-2 Inhibitor Axitinib
by: Linda Heintze, et al.
Published: (2020-11-01)

Comparison of small molecules VEGFR inhibitors in the treatment of renal cell carcinoma
by: Jie Yi Tan, et al.
Published: (2023-07-01)

Biophysical and computational characterization of vandetanib–lysozyme interaction
by: Kabir, Md Zahirul, et al.
Published: (2018)

Investigating the effect of vandetanib and celecoxib combination on angiogenesis
by: Abdul Qadir, MPhil, et al.
Published: (2023-10-01)

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
by: Wu-tong Ju, et al.
Published: (2022-09-01)

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
by: Katja Seipel, et al.
Published: (2021-02-01)

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma
by: Malcy Tarin, et al.
Published: (2023-04-01)

Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs
by: Bih-Rong Wei, et al.
Published: (2022-12-01)

Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
by: Tomer Meirson, et al.
Published: (2020-06-01)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
by: Emmanuelle M. Ruiz, et al.
Published: (2023-05-01)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
by: Stefanie Hoyer, et al.
Published: (2021-11-01)

Combining HDAC and MEK Inhibitors with Radiation against Glioblastoma-Derived Spheres
by: Eno I. Essien, et al.
Published: (2022-02-01)

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
by: Yahong Liu, et al.
Published: (2023-09-01)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
by: Karisa C. Schreck, et al.
Published: (2019-08-01)

Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats
by: Yvonne Füll, et al.
Published: (2022-12-01)

Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model
by: Wael A. Alanazi, et al.
Published: (2023-02-01)